Cargando…

The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls)

BACKGROUND: The isoxazolines are a novel class of parasiticides that are potent inhibitors of γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and, to a lesser extent, of inhibitory glutamate-gated chloride channels (GluCls). Lotilaner (Credelio™), a novel representative of this chemical...

Descripción completa

Detalles Bibliográficos
Autores principales: Rufener, Lucien, Danelli, Vanessa, Bertrand, Daniel, Sager, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664438/
https://www.ncbi.nlm.nih.gov/pubmed/29089046
http://dx.doi.org/10.1186/s13071-017-2470-4
_version_ 1783274998413131776
author Rufener, Lucien
Danelli, Vanessa
Bertrand, Daniel
Sager, Heinz
author_facet Rufener, Lucien
Danelli, Vanessa
Bertrand, Daniel
Sager, Heinz
author_sort Rufener, Lucien
collection PubMed
description BACKGROUND: The isoxazolines are a novel class of parasiticides that are potent inhibitors of γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and, to a lesser extent, of inhibitory glutamate-gated chloride channels (GluCls). Lotilaner (Credelio™), a novel representative of this chemical class, is currently evaluated for its excellent ectoparasiticide properties. METHODS: In this study, we investigated the molecular mode of action and pharmacology of lotilaner. We report the successful gene identification, cDNA cloning and functional expression in Xenopus oocytes of Drosohpila melanogaster (wild type and dieldrin/fipronil-resistant forms), Lepeophtheirus salmonis (an ectoparasite copepod crustacean of salmon), Rhipicephalus microplus and Canis lupus familiaris GABACls. Automated Xenopus oocyte two-electrode voltage clamp electrophysiology was used to assess GABACls functionality and to compare ion channel inhibition by lotilaner with that of established insecticides addressing GABACls as targets. RESULTS: In these assays, we demonstrated that lotilaner is a potent non-competitive antagonist of insects (fly) GABACls. No cross-resistance with dieldrin or fipronil resistance mutations was detected, suggesting that lotilaner might bind to a site at least partly different from the one bound by known GABACl blockers. Using co-application experiments, we observed that lotilaner antagonism differs significantly from the classical open channel blocker fipronil. We finally confirmed for the first time that isoxazoline compounds are not only powerful antagonists of GABACls of acari (ticks) but also of crustaceans (sea lice), while no activity on a dog GABA(A) receptor was observed up to a concentration of 10 μM. CONCLUSIONS: Together, these results demonstrate that lotilaner is a non-competitive antagonist specific to invertebrate’s γ-aminobutyric acid-gated chloride channels (GABACls). They contribute to our understanding of the mode of action of this new ectoparasiticide compound. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-017-2470-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5664438
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56644382017-11-08 The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls) Rufener, Lucien Danelli, Vanessa Bertrand, Daniel Sager, Heinz Parasit Vectors Research BACKGROUND: The isoxazolines are a novel class of parasiticides that are potent inhibitors of γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and, to a lesser extent, of inhibitory glutamate-gated chloride channels (GluCls). Lotilaner (Credelio™), a novel representative of this chemical class, is currently evaluated for its excellent ectoparasiticide properties. METHODS: In this study, we investigated the molecular mode of action and pharmacology of lotilaner. We report the successful gene identification, cDNA cloning and functional expression in Xenopus oocytes of Drosohpila melanogaster (wild type and dieldrin/fipronil-resistant forms), Lepeophtheirus salmonis (an ectoparasite copepod crustacean of salmon), Rhipicephalus microplus and Canis lupus familiaris GABACls. Automated Xenopus oocyte two-electrode voltage clamp electrophysiology was used to assess GABACls functionality and to compare ion channel inhibition by lotilaner with that of established insecticides addressing GABACls as targets. RESULTS: In these assays, we demonstrated that lotilaner is a potent non-competitive antagonist of insects (fly) GABACls. No cross-resistance with dieldrin or fipronil resistance mutations was detected, suggesting that lotilaner might bind to a site at least partly different from the one bound by known GABACl blockers. Using co-application experiments, we observed that lotilaner antagonism differs significantly from the classical open channel blocker fipronil. We finally confirmed for the first time that isoxazoline compounds are not only powerful antagonists of GABACls of acari (ticks) but also of crustaceans (sea lice), while no activity on a dog GABA(A) receptor was observed up to a concentration of 10 μM. CONCLUSIONS: Together, these results demonstrate that lotilaner is a non-competitive antagonist specific to invertebrate’s γ-aminobutyric acid-gated chloride channels (GABACls). They contribute to our understanding of the mode of action of this new ectoparasiticide compound. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-017-2470-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-11-01 /pmc/articles/PMC5664438/ /pubmed/29089046 http://dx.doi.org/10.1186/s13071-017-2470-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Rufener, Lucien
Danelli, Vanessa
Bertrand, Daniel
Sager, Heinz
The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls)
title The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls)
title_full The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls)
title_fullStr The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls)
title_full_unstemmed The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls)
title_short The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls)
title_sort novel isoxazoline ectoparasiticide lotilaner (credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (gabacls)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664438/
https://www.ncbi.nlm.nih.gov/pubmed/29089046
http://dx.doi.org/10.1186/s13071-017-2470-4
work_keys_str_mv AT rufenerlucien thenovelisoxazolineectoparasiticidelotilanercredelioanoncompetitiveantagonistspecifictoinvertebratesgaminobutyricacidgatedchloridechannelsgabacls
AT danellivanessa thenovelisoxazolineectoparasiticidelotilanercredelioanoncompetitiveantagonistspecifictoinvertebratesgaminobutyricacidgatedchloridechannelsgabacls
AT bertranddaniel thenovelisoxazolineectoparasiticidelotilanercredelioanoncompetitiveantagonistspecifictoinvertebratesgaminobutyricacidgatedchloridechannelsgabacls
AT sagerheinz thenovelisoxazolineectoparasiticidelotilanercredelioanoncompetitiveantagonistspecifictoinvertebratesgaminobutyricacidgatedchloridechannelsgabacls
AT rufenerlucien novelisoxazolineectoparasiticidelotilanercredelioanoncompetitiveantagonistspecifictoinvertebratesgaminobutyricacidgatedchloridechannelsgabacls
AT danellivanessa novelisoxazolineectoparasiticidelotilanercredelioanoncompetitiveantagonistspecifictoinvertebratesgaminobutyricacidgatedchloridechannelsgabacls
AT bertranddaniel novelisoxazolineectoparasiticidelotilanercredelioanoncompetitiveantagonistspecifictoinvertebratesgaminobutyricacidgatedchloridechannelsgabacls
AT sagerheinz novelisoxazolineectoparasiticidelotilanercredelioanoncompetitiveantagonistspecifictoinvertebratesgaminobutyricacidgatedchloridechannelsgabacls